Abstract
Precision oncology has made progress in recent years and is currently at the heart of revolutionizing cancer research. In May 2019, two comprehensive genomic profiling (CGP) tests were approved with reimbursement in Japan: FoundationOne CDx Cancer Genomic Profile and OncoGuide NCC Oncopanel System, which are fully covered by the national health insurance system. It has been reported that only 3.7% of patients received sequencing-directed therapy (Sunami et al., Int J Clin Oncol, 2021). The Ministry of Health, Labor and Welfare reported that in 2021, only 8.1% of patients received sequencing-directed therapy after CGP tests.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
